Motor Neuron Disease Market

Market Overview:

The 7 major motor neuron disease markets reached a value of US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.

The motor neuron disease market has been comprehensively analyzed in IMARC's new report titled "Motor Neuron Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Motor neuron disease refers to a group of progressive neurological disorders that affect the nerve cells responsible for controlling voluntary muscle movement. Some of the common symptoms include muscle weakness, often beginning in the hands, feet, or limbs; muscle stiffness and cramps; difficulty with coordination and balance; slurred or impaired speech; problems in swallowing; muscle twitching; muscle atrophy, etc. As the condition progresses, patients may experience increased difficulty with mobility, such as walking and fine motor tasks, as well as respiratory disorders. The diagnosis of motor neuron disease involves a comprehensive evaluation by healthcare professionals, typically including a neurologist. It begins with a detailed medical history and physical examination to assess symptoms, progression, and any family history of the ailment. Several diagnostic procedures, such as electromyography (EMG) and nerve conduction studies, can help determine the integrity of motor neurons as well as rule out further potential causes of muscle weakness. Numerous additional investigations, including blood tests, neuroimaging (MRI), lumbar puncture, etc., may be conducted to exclude other conditions and gather supportive evidence for confirming the diagnosis.

The increasing prevalence of inherited genetic mutations that can disrupt normal cellular processes, thereby leading to motor neuron degeneration, is primarily driving the motor neuron disease market. In addition to this, the growing cases of oxidative stress, caused by an imbalance between the production of reactive oxygen species and the body's ability to neutralize them, that lead to cellular damage are also creating a positive outlook for the market. Moreover, the widespread adoption of riluzole, which works by reducing glutamate levels in the brain, for slowing down disease progression and prolonging survival in patients is further bolstering the market growth. Additionally, various key players are making significant investments in R&D activities for introducing disease-modifying therapies that can reduce neuroinflammation, promote neuronal survival, enhance mitochondrial function, and target genetic mutations associated with the ailment. This, in turn, is also augmenting the market growth. Furthermore, the inflating demand for neuroprotective agents, such as antioxidants, mitochondrial regulators, glutamate modulators, etc., since they address oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity, is expected to drive the motor neuron disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the motor neuron disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for motor neuron disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the motor neuron disease market in any manner.

Recent Developments:

• In February 2024, Biogen Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY (tofersen) for the treatment of adults with amyotrophic lateral sclerosis caused by a mutation in the superoxide dismutase 1 gene.

Key Highlights:

• Motor neuron disease affects 4·5 (4·1-5·0) out of 100,000 people worldwide.
• Motor neuron disease affects roughly two out of every 100,000 people in the United Kingdom each year, with approximately 5,000 people living with the condition at any given time.
• In the United States, around 5,600 people are diagnosed each year.
• The incidence of motor neuron disease increases with age, increasing between the ages of 75 to 79 and subsequently decreasing.
• The crude rate of motor neuron disease is higher in men than in women, at 4.3 per 100,000 men per year vs 3.1 per 100,000 women per year.

Drugs:

Tiglutik (Riluzole) is an oral suspension (mildly thick liquid) of riluzole. This medication is used to treat individuals with amyotrophic lateral sclerosis or motor neuron disease. TIGLUTIK is predicted to work by inhibiting glutamate activation.

Tofersen is an antisense oligonucleotide (ASO) that binds to SOD1 mRNA, reducing SOD1 protein synthesis. Tofersen has been granted fast approval by the U.S. Food and Drug Administration to treat amyotrophic lateral sclerosis in adults with a mutation in the superoxide dismutase 1 (SOD1) gene.

Masitinib is an oral tyrosine kinase inhibitor that inhibits macrophage and mast cell growth while increasing apoptosis and lowering neuroinflammatory response. Masitinib inhibits a biological enzyme termed tyrosine kinase, which is thought to be involved in tissue inflammation. Inflammation in the brain and spinal cord is thought to help motor neuron disease progress. Reducing the activity of inflammatory cells in the brain may help to protect motor neurons.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the motor neuron disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the motor neuron disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current motor neuron disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the motor neuron disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the motor neuron disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the motor neuron disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of motor neuron disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of motor neuron disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of motor neuron disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with motor neuron disease across the seven major markets?
• What is the size of the motor neuron disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of motor neuron disease?
• What will be the growth rate of patients across the seven major markets?
   

Motor Neuron Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for motor neuron disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the motor neuron disease market?
• What are the key regulatory events related to the motor neuron disease market?
• What is the structure of clinical trial landscape by status related to the motor neuron disease market?
• What is the structure of clinical trial landscape by phase related to the motor neuron disease market?
• What is the structure of clinical trial landscape by route of administration related to the motor neuron disease market?